So far, it is uncertain whether in vivo application of tribody [(HER2)2×Vγ9] or similar bispecific antibodies in the presence or absence of IDO inhibitors or other inhibitors can overcome an immunosuppressive tumor microenvironment by targeting tumor-infiltrating γδ T cells to tumor cells. Here, IDO1 is linked to neoplasm.